Pharmacological stabilization of the DYRK2 protein is expected to be beneficial for CML patients, as it abrogates the self-renewal capacity of LSCs by depleting c-MYC and induces their apoptosis by activating p5380,83,87. The gene discussed is DYRK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.